Antitumor activity of NPB001-05, an orally active inhibitor of Bcr-Abl tyrosine kinase

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 4, 2011, Pages 1349-1364

  Wagh, Vilas ^a   Mishra, Prabha ^a   Thakkar, Arvind ^a   Shinde, Vaibhav ^a   Sharma, Somesh ^a   Padigaru, Muralidhara ^a   Joshi, Kalpana ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Bcr Abl; Chronic myelogenous leukemia; Imatinib; Kinase mutation; Piper betle; T315I

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CASPASE 3; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NPB 001 05; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; ENZYME INHIBITOR; NPB001 05; NPB001-05; PLANT EXTRACT; PRIMER DNA; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; GENE EXPRESSION; IMMUNOPRECIPITATION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; HUMAN; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION;

ANIMALIA; PIPER BETLE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA PRIMERS; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; MALE; MICE; MICE, SCID; PLANT EXTRACTS; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80053613848     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. J. M. Pezzuto. Plant-derived anticancer agents. Biochemical Pharmacology 53, 121-33 (1997) (Pubitemid 27013467)
2. J. Wu, Y. J. Wu, B. B. Yang. Anticancer activity of Hemsleya amabilis extract. Life Sciences 71, 2161-70 (2002)
3. R. S. Di Paola, H. Y. Zhang, G. H. Lambert, R. Meeker, E. Licitra, M. M. Rafi, B. Zhu, H. Spaulding, S. Goodin, M. Toledano, W. Hait, M. Gallo. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. New England Journal of Medicine 339, 785-91 (1998) (Pubitemid 28447451)
4. S. Moalic, B. Liagre, C. Corbiere, A. Bianchi, M. Dauca, K. Bordji, J. Beneytout. A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells. Febs Letters 506, 225-30 (2001) (Pubitemid 32964818)
5. S. Gupta, K. Hastak, N. Ahmad, J. S. Lewin, H. Mukhtar. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proceedings of the National Academy of Sciences of the United States of America 98, 10350-5 (2001) (Pubitemid 32803023)
6. Anonymous. The Wealth of India: The Dictionary of Indian Raw Materials and Industrial Products. Raw Material, revised edition Publication and Information directorate, CSIR, New Delhi 5, 84-94 (1992)
7. N. Ramji, N. Ramji, R. Iyer, S. Chandrasekaran. Phenolic antibacterials from Piper betle in the prevention of halitosis. Journal of Ethnopharmacology 83, 149-52 (2002) (Pubitemid 36164740)
8. M. S. Prabhu, K. Platel, G. Saraswathi, K. Srinivasan. Effect of orally administered betel leaf (Piper betle Linn.) on digestive enzymes of pancreas and intestinal mucosa and on bile production in rats. Indian J Exp Biol 33, (1995)
9. D. Choudhary, R. K. Kale. Antioxidant and non-toxic properties of Piper belle leaf extract: in vitro and in vivo studies. Phytotherapy Research 16, 461-6 (2002) (Pubitemid 34947958)
10. R. Saravanan, A. Prakasam, B. Ramesh, K. V. Pugalendi. Influence of Piper betle on hepatic marker enzymes and tissue antioxidant status in ethanol-treated Wistar rats. J Med Food 5, (2002)
11. L. C. M. Row, J. C. Ho. The Antimicrobial Activity, Mosquito Larvicidal Activity, Antioxidant Property and Tyrosinase Inhibition of Piper betle. Journal of the Chinese Chemical Society 56, 653-8 (2009)
12. N. Dasgupta, B. De. Antioxidant activity of Piper betle L.leaf extract in vitro. Food Chemistry 88, 219-24 (2004) (Pubitemid 38887362)
13. J. S. Rathee, B. S. Patro, S. Mula, S. Gamre, S. Chattopadhyay. Antioxidant activity of Piper betel leaf extract and its constituents. Journal of Agricultural and Food Chemistry 54, 9046-54 (2006) (Pubitemid 44953600)
14. S. Bhattacharya, D. Banerjee, A. K. Bauri, S. Chattopadhyay, S. K. Bandyopadhyay. Healing property of the Piper betel phenol, allylpyrocatechol against indomethacin-induced stomach ulceration and mechanism of action. World Journal of Gastroenterology 13, 3705-13 (2007) (Pubitemid 47207731)
15. L. S. R. Arambewela, L. D. A. M. Arawwawala, W. D. Ratnasooriya. Antidiabetic activities of aqueous and ethanolic extracts of Piper betle leaves in rats. Journal of Ethnopharmacology 102, 239-45 (2005) (Pubitemid 41483565)
16. V. A. Facundo, A. S. P. Da Silveira, S. M. Morais. Constituents of Piper alatabaccum Trel & Yuncker (Piperaceae). Biochemical Systematics and Ecology 33, 753-6 (2005) (Pubitemid 40607861)
17. Ferenc Hollosy, Gyorgy Keri. Plant-derived protein tyrosine kinase inhibitors as anticancer agents. Curr Med Chem Anticancer Agents 4, (2004)
18. C. R. Bartram, A. Deklein, A. Hagemeijer, T. Vanagthoven, A. G. Vankessel, D. Bootsma, G. Grosveld, M. Freguson-Smith, T. Davies, M. Stone, N. Heisterkamp. Stephenson, J. Groffen. Translocation of C-Abl Oncogene Correlates with the Presence of A Philadelphia-Chromosome in Chronic Myelocytic-Leukemia. Nature 306, 277-80 (1983) (Pubitemid 14232360)
19. T. G. Lugo, A. M. Pendergast, A. J. Muller, O. N. Witte. Tyrosine Kinase-Activity and Transformation Potency of Bcr-Abl Oncogene Products. Science 247, 1079-82 (1990)
20. B. J. Druker. - Imatinib as a paradigm of targeted therapies. - Adv Cancer Res, (2004)
21. S. G. O'Brien, F. Guilhot, R. A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. Cornelissen, T. Fisher, A. Hochhaus, T. Hughes, K. Lechner, J. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A. Bolton, R. Capdeville, B. Druker. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine 348, 994-1004 (2003) (Pubitemid 36302244)
22. A. Hochhaus, S. G. O'Brien, F. Guilhot, B. J. Druker, S. Branford, L. Foroni, J. Goldman, M. Mueller, J. Radich, M. Rudoltz, M. Mone, I. Gathmann, T. Hughes, R. Larson. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054-61 (2009)
23. N. P. Shah, J. M. Nicoll, B. Nagar, M. E. Gorre, R. L. Paquette, J. Kuriyan, C. Sawyers. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-25 (2002) (Pubitemid 41039112)
24. P. Sharma, S. Mohanty, V. Kochupillai, L. Kumar. Mutations in ABL kinase domain are associated with inferior progression-free survival. Leukemia & Lymphoma 51, 1072-8 (2010)
25. B. J. Druker. Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808-17 (2008)
26. N. P. Shah, C. Tran, F. Y. Lee, P. Chen, D. Norris, C. L. Sawyers. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004) (Pubitemid 38938156)
27. E. Weisberg, P. W. Manley, W. Breitenstein, J. Bruggen, S. W. Cowan-Jacob, A. Ray, B. Huntly, D. Fabbro, G. Fendrich, E. Hall-Meyers, A. Kung, J. Mestan, G. Daley, L. Callahan, L. Catley, C. Cavazza, M. Ayam, D. Neuberg, R. Wright, D. Gilliland, J. Griffin. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-41 (2005) (Pubitemid 40248339)
28. N. C. Wolff, D. R. Veach, W. P. Tong, W. G. Bornmann, B. Clarkson, R. L. Ilaria. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105, 3995-4003 (2005) (Pubitemid 40656148)
29. N. Raje, T. Hideshima, S. Mukherjee, M. Raab, S. Vallet, S. Chhetri, D. Cirstea, S. Pozzi, C. Mitsiades, M. Rooney, T. Kizltepe, K. Podar, Y. Okawa, H. Ikeda, R. Carrasco, P. Richardson, D. Chauhan, N. Munshi, S. Sharma, H. Parikh, B. Chabner, D. Scadden, K. Anderson. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 23, 961-70 (2009)
30. H. W. Hirte, D. Raghunadharao, T. Baetz, S. Hotte, S. Rajappa, A. Lacobucci, S. Sharma, H. Parikh, S. Kulkarni, S. Patil, S. Gaston. A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. Mol Cancer Ther 6, 3371S (2007)
31. C. B. Lozzio, B. B. Lozzio. Human Chronic Myelogenous Leukemia Cell-Line with Positive Philadelphia Chromosome. Blood 45, 321-34 (1975)
32. P. La Rosee, A. S. Corbin, E. P. Stoffregen, M. W. Deininger, B. J. Druker. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, ST1571). Cancer Res 62, 7149-53 (2002) (Pubitemid 36025227)
33. Freshney R. Culture of Animal-Cells - A Manual of Basic Technique. New York: Wiley-Liss Inc 4th edn, 330 (2000)
34. S. Pereira, P. Veeraraghavan, S. Ghosh, M. Gandhi. Animal experimentation and ethics in India: The CPCSEA makes a difference. Atla-Alternatives to Laboratory Animals 32, 411-5 (2004) (Pubitemid 38843418)
35. K. S. Joshi, M. J. Rathos, P. Mahajan, V. Wagh, S. Shenoy, D. Bhatia, S. Chile, M. Shivakumar, A. Maier, H. Fiebig, S. Sharma. P276-00, a novel cyclin-dependent inhibitor induces G (1)-G (2) arrest, shows antitumor activity on cisplatin-reasistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 6, 926-34 (2007) (Pubitemid 46554562)
36. D. Edwards. Non-linear normalization and background correction in one-channel cDNA microarray studies. Bioinformatics 19, 825-33 (2003) (Pubitemid 36582398)
37. M. B. Eisen, P. T. Spellman, P. O. Brown, D. Botstein. Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 95, 14863-8 (1998) (Pubitemid 29003722)
38. S. Tavazoie, J. D. Hughes, M. J. Campbell, R. J. Cho, G. M. Church. Systematic determination of genetic network architecture. Nature Genetics 22, 281-5 (1999) (Pubitemid 29297256)
39. J. T. Auman, G. A. Boorman, R. E. Wilson, G. S. Travlos, R. S. Paules. Heat map visualization of highdensity clinical chemistry data. Physiological Genomics 31, 352-6 (2007) (Pubitemid 350014411)
40. M. B. Eisen, P. T. Spellman, P. O. Brown, D. Botstein. Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 95, 14863-8 (1998) (Pubitemid 29003722)
41. P. D. Thomas, M. J. Campbell, A. Kejariwal, H. Y. Mi, B. Karlak, R. Daverman, K. Diemer, A. Muruganujan, A. Narechania. PANTHER: A library of protein families and subfamilies indexed by function. Genome Research 13, 2129-41 (2003) (Pubitemid 37161770)
42. S. Rozen, H. Skaletsky. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132, (2000)
43. K. J. Livak, T. D. Schmittgen. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (T) (-Delta Delta C) method. Methods 25, 402-8 (2001) (Pubitemid 34164012)
44. K. S. Joshi, M. J. Rathos, R. D. Joshi, M. Sivakumar, M. Mascarenhas, S. Kamble, B. Lal, S. Sharma. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 6, 918-25 (2007) (Pubitemid 46554561)
45. J. X. Liu, Y. Wu, R. B. Arlinghaus. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 56, 5120-4 (1996) (Pubitemid 26383022)
46. M. D. Abramoff, P. J. Magelhaes, S. J. Ram. Image Processing with ImageJ. Biophotonics International 11, 36-42 (2004)
47. X. G. Sun, P. Majumder, H. Shioya, F. Wu, S. Kumar, R. Weichselbaum, S. Kharbanda, D. Kufe. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J Biol Chem 275, 17237-40 (2000) (Pubitemid 30430754)
48. E. Kojima, A. Takeuchi, M. Haneda, F. Yagi, T. Hasegawa, K. Yamaki, K. Takeda, S. Akira, K. Shimokata, K. Isobe. The function of GADD34 is a recovery from a shutoff of protein synthesis induced by ER stress - elucidation by GADD34-deficient mice. Faseb Journal 17, 1573-+ (2003)
49. A. Hochhaus, P. La Rosee. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18, 1321-31 (2004) (Pubitemid 39136739)
50. T. Schindler, W. Bornmann, P. Pellicena, W. T. Miller, B. Clarkson, J. Kuriyan. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938-42 (2000)
51. A. Hochhaus, S. Kreil, A. S. Corbin, P. La Rosee, M. C. Muller, T. Lahaye, B. Hanfstein, C. Schoch, N. Cross, U. Berger, H. Gschaidmeier, B. Druker, R. Hehlmann. Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy. Leukemia 16, 2190-6 (2002) (Pubitemid 35331833)
52. G. Bandyopadhyay, T. Biswas, K. C. Roy, S. Mandal, C. Mandal, B. C. Pal, S. Bhattacharya, S. Rakshit, D. Bhattacharya, U. Chaudhuri, A. Konar, S. Bandyopadhyay. Chlorogenic acid-inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood 104, 2514-22 (2004) (Pubitemid 39331855)
53. S. C. Young, C. J. Wang, J. J. Lin, P. L. Peng, J. L. Hsu, F. P. Chou. Protection effect of piper betel leaf extract against carbon tetrachloride-induced liver fibrosis in rats. Archives of Toxicology 81, 45-55 (2007)
54. J. M. Thornburg, K. K. Nelson, B. F. Clem, A. N. Lane, S. Arumugam, A. Simmons, J. Eato, S. Telang, J. Chesney. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Research 10, (2008)
55. K. Tarao, Y. Rino, S. Ohkawa, A. Shimizu, S. Tamai, K. Miyakawa, H. Aoki, T. Imada, K. Shindo, N. Okamoto, S. Tostsuka. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 86, 589-95 (1999) (Pubitemid 29379404)
56. A. J. Amonkar, P. R. Padma, S. V. Bhide. Protective Effect of Hydroxychavicol, A Phenolic Component of Betel Leaf, Against the Tobacco-Specific Carcinogens. Mutation Research 210, 249-53 (1989) (Pubitemid 19036254)
57. A. J. Amonkar, M. Nagabhushan, A. V. Dsouza, S. V. Bhide. Hydroxychavicol - A New Phenolic Antimutagen from Betel Leaf. Food and Chemical Toxicology 24, 1321-4 (1986) (Pubitemid 17215893)
58. M. Gordaliza. Natural products as leads to anticancer drugs. Clinical & Translational Oncology 9, 767-76 (2007)
59. D. A. Kennedy, J. Hart, D. Seely. Cost Effectiveness of Natural Health Products: A Systematic Review of Randomized Clinical Trials. Evidence-Based Complementary and Alternative Medicine 6, 297-304 (2009)
60. R. Kerkela, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, C. Beahm, B. Walters, S. Shevtsov, S. Pesant, F. Clubb, A. Rosenzweig, R. Salomon, R. Van-Etten, J. Alroy, J. Durand, T. Force. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine 12, 908-16 (2006) (Pubitemid 44175142)
61. A. T. Van Oosterom, I. Judson, J. Verweij, S. Stroobants, E. D. Di Paola, S. Dimitrijevic, M. Martens, A. Webb, R. Sciot, M. Van-Glabbeke, S. Silberman, O. Nielsen. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-3 (2001) (Pubitemid 33055745)
62. C. Robert, J. C. Soria, A. Spatz, A. Le Cesne, D. Malka, P. Pautier, J. Wechsler, C. Lhomme, B. Escudier, V. Boige, J. Armand, T. Le-Chevalier. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncology 6, 491-500 (2005) (Pubitemid 40903630)
63. A. S. M. Yong, J. V. Melo. The impact of gene profiling in chronic myeloid leukaemia. Best Practice & Research Clinical Haematology 22, 181-90 (2009)
64. T. R. Golub, D. K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, J. P. Mesirov, H. Coller, M. Loh, J. Downing, M. Caligiuri, C. Bloomfield, E. Lander. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286, 531-7 (1999)
65. S. Ramaswamy, P. Tamayo, R. Rifkin, S. Mukherjee, C. H. Yeang, M. Angelo, C. Ladd, M. Reich, E. Latulippe, J. Mesirov, T. Poggio, W. Gerald, M. Loda, E. Lander, T. Golub. Multiclass cancer diagnosis using tumor gene expression signatures. Proceedings of the National Academy of Sciences of the United States of America 98, 15149-54 (2001) (Pubitemid 34013984)
66. M. A. Shipp, K. N. Ross, P. Tamayo, A. P. Weng, J. L. Kutok, R. C. T. Aguiar, M. Gaasenbeek, M. Angelo, M. Reich, G. Pinkus, T. Ray, M. Koval, K. Last, A. Norton, A. Lister, J. Mesirov, D. Neuberg, E. Lander, J. Aster, T. Golub. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine 8, 68-74 (2002) (Pubitemid 34101731)
67. J. P. Radich, H. Y. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah, W. Stock, C. Willman, S. Friend, P. Linsley. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 103, 2794-9 (2006)
68. S. A. Armstrong, J. E. Staunton, L. B. Silverman, R. Pieters, M. L. De Boer, M. D. Minden, S. Sallan, E. Lander, T. Golub, S. Korsmeyer. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics 30, 41-7 (2002)
69. L. Pattacini, M. Mancini, L. Mazzacurati, G. Brusa, M. Benvenuti, G. Martinelli, M. Baccarani, M. Santucci. Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase. Leukemia Research 28, 191-202 (2004) (Pubitemid 37487999)